To test our hypothesis, we used an MC38 (p-53 mutant, K-RAS wild-type, MSI-H) orthotopic tumor-bearing mouse model and treated it with Mit-A combined with αPD-L1 mAb. This evidence concerns the gene KRAS and neoplasm.